Under one in 10 patients eligible to benefit from GLP-1 drugs including Wegovy have access to them, states the World Health Organization as it issues its inaugural recommendations on the medications.
Given more than one billion individuals worldwide now classified as obese, it is calling for increased and just access to this class of drugs.
Per estimates, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"The latest guidance affirms that obesity is a long-term condition that can be addressed with comprehensive and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are significant obstacles to widespread access to the jabs that can help people shift significant body mass, says the organization.
Weight-Loss Drug Shortage
Even in the present most optimistic scenario, the manufacturing of these medications could only cover about 100 million people – less than 10% of eligible patients, according to the health organization.
The recommendation urges nations and manufacturers to increase access, through strategies such as licensing agreements.
A patent on the active ingredient – the primary ingredient of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.
The Way Obesity Jabs Operate
These medications replicate a biological compound to delay gastric emptying, reduce hunger and enhance feelings of fullness so people consume fewer calories.
Patients usually start to lose weight after several weeks of starting on the regular doses.
Research indicates people may regain a significant portion within a year of stopping the medication, as their typical appetite come back.
To be overweight or obese increases your risk for experiencing diseases, like type 2 diabetes, heart disease, stroke, and certain malignancies.
Excess weight affects individuals in all nations and was linked to millions of deaths worldwide in 2024, per the WHO.
